March 29, 2022, North Land and the Bethune Public Welfare Foundation held a signing ceremony for the “Continuous Learning and Excellence—Vascular Regenerative Medicine Research” project donation. Mr. Xu Songshan, Chairman of the company, and Ms. Tian Xiaoli, Secretary-General of the Bethune Public Welfare Foundation, signed the agreement on-site. The Bethune Public Welfare Foundation presented the company with a “Caring Enterprise” certificate. Vice President Han Chengquan of the company, Deputy Secretary-General Yang Yi of the foundation, and other staff members jointly witnessed the signing ceremony.

        This time, the company has joined forces with the Bethune Public Welfare Foundation to establish a special funding program for “Vascular Regenerative Medicine Research.” The goal is to leverage the complementary strengths of both organizations, encourage more clinicians to participate in basic and clinical research in the field of vascular regeneration, promote innovation in medical technology, enhance the level of healthcare services, and contribute to the development of China’s medical sector and social welfare initiatives.

        The Bethune Public Welfare Foundation is responsible for managing this special fund. Based on the intended use of the project funds, it will select and support outstanding projects in the field of vascular regenerative medicine, while also overseeing the implementation process, evaluating research outcomes, and ensuring research quality.

The Bethune Public Welfare Foundation is a public-benefit charitable organization with independent legal status, under the supervision of China’s Ministry of Civil Affairs. It inherits and promotes the great spirit and noble character of the internationalist fighter Bethune, guided by the principles of humanity, responsibility, and legacy. The Foundation builds a public-benefit charitable platform in the healthcare sector, extensively carries out compassionate public welfare projects, alleviates the burdens and difficulties faced by the nation, and strives to improve China’s social assistance mechanisms.

        NORTHLAND is a high-tech enterprise specializing in the R&D, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. The company is currently transitioning from a pure R&D-oriented enterprise to an integrated model encompassing R&D, production, and sales. It is now preparing to establish an industrial base for biopharmaceuticals and is actively gearing up for commercialization. The company has developed 13 biopharmaceutical products covering 15 indications; among these, three biopharmaceuticals have entered the clinical research stage, and several ophthalmic drugs are already on the market and being sold.

        Both parties will fully leverage their respective resources and complementary strengths to jointly organize public welfare activities, establish specialized committees, and engage in the development of clinical medication guidelines and consensus statements on clinical treatment, thereby continuously deepening and broadening their cooperation.

        Xu Songshan, Chairman of the company, expressed admiration for the Bethune Public Welfare Foundation's efforts and achievements in public welfare, and praised the foundation's efficient and standardized operations. He stated that in the near future, after NORTHLAND’s pipeline products are launched, the company will actively engage in more social公益 activities, implement ESG business principles, and leverage technology to support a Healthy China. “Great love knows no bounds; compassion is limitless.” While pursuing the company’s sustainable development, we will dedicate our care and strength to the common prosperity of the entire society.